Abstract
BackgroundThe majority of patients with pancreatic ductal adenocarcinoma (PDAC) fail to derive any durable responses from single agent immune checkpoint blockade therapy. This refractory state originates from PDAC's unique tumor...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have